Yasuo Fujii
Director/Board Member en ORCHARD THERAPEUTICS PLC .
Perfil
Yasuo Fujii is currently a Director at Orchard Therapeutics Plc and a Chief Strategy Officer at Kyowa Kirin Co., Ltd.
He previously worked as an Executive Vice President-Corporate Planning at Kyowa Kirin International Plc.
Mr. Fujii holds an MBA from the University of Illinois.
Cargos activos de Yasuo Fujii
Empresas | Cargo | Inicio |
---|---|---|
KYOWA KIRIN CO. LTD. | Corporate Officer/Principal | 01/04/1988 |
ORCHARD THERAPEUTICS PLC | Director/Board Member | 24/01/2024 |
Antiguos cargos conocidos de Yasuo Fujii.
Empresas | Cargo | Fin |
---|---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Corporate Officer/Principal | - |
Formación de Yasuo Fujii.
University of Illinois | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
KYOWA KIRIN CO. LTD. | Health Technology |
Empresas privadas | 2 |
---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Yasuo Fujii